Ms. Morris has experience with all stages of patent litigation, including motion practice, fact and expert discovery, and trial. Representative matters include:
- In re Bendamustine Consolidated Cases, No. 13-cv-02046 (D. Del.): Represented plaintiff Cephalon, Inc. in patent litigation against over 15 defendants involving Cephalon’s TREANDA® (bendamustine HCl) lyophilized product. The case went to trial before the Honorable Gregory Sleet in December 2015. After a trial against five defendants, Cephalon prevailed at the district court on its claims of infringement against all defendants.
- Endo Pharmaceuticals et al. v. Teva Pharmaceuticals USA et al. (D. Del.): Represented defendant Teva Pharmaceuticals in Hatch-Waxman patent litigation involving Endo’s OPANA ER® (extended-release oxymorphone hydrochloride) tablets. The case went to trial before the Honorable Richard G. Andrews in July 2016.
- Merz Pharmaceuticals et al. v. Taro Pharmaceuticals U.S.A., et al. (S.D.N.Y): Representing defendant Taro Pharmaceuticals in Hatch-Waxman patent litigation involving Merz’s NAFTIN® Gel, 2% (naftifine hydrochloride) product.
- Eli Lilly v. Teva Pharmaceuticals USA (S.D. Ind.): Representing defendant Teva Pharmaceuticals in Hatch-Waxman patent litigation involving Eli Lilly’s FORTEO® (teriparatide) injectable product.
- Lupin Atlantis Holdings v. Invagen Pharmaceuticals (D. Del.): Representing plaintiff Lupin in Hatch-Waxman patent litigation involving Lupin’s ANTARA® (fenofibrate) product.
While attending law school, Ms. Morris was the co-symposium editor for the American Journal of Law and Medicine. Also while at law school, Ms. Morris was a research assistant for Professor Kenneth W. Simons.
While in law school, Ms. Morris completed an internship with the Massachusetts Commission Against Discrimination (MCAD). Prior to law school, Ms. Morris worked for Australia’s Department of Foreign Affairs and Trade (DFAT) and Department of Defence.